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Objective:Recommendations for aortic valve replacement in severe aortic stenosis are
based primarily on the presence of symptoms. However, the onset of symptoms is of-
ten insidious, potentially leading to delayed intervention and suboptimal results. Iden-
tifying factors that reduce the survival of patients undergoing aortic valve replacement
could lead to revised treatment guidelines and improved outcomes.
Methods: We conducted a single-center observational clinical study of 3049 patients
with aortic stenosis who underwent native aortic valve replacement with a single type
of bioprosthesis. The primary end point was all-cause mortality from the date of op-
eration. Multivariable analysis of risk factors for death was performed in the multi-
phase hazard function domain.
Results: The presence of severe left ventricular hypertrophy at operation, which pre-
ceded symptoms in 17% of patients, was associated with decreased survival. This
effect was magnified by the severity of aortic stenosis (P5 .02) and use of small pros-
theses (P 5 .01). The presence of left ventricular dysfunction reduced survival (P 5
.0003). Although older age was a risk factor for death (P , .0001), elderly patients
had survival comparable to their age, race, and sex-matched cohorts, whereas younger
patients had worse than expected survival that was further diminished with insertion
of a small prosthesis (P 5 .01).
Conclusion: To optimize survival, earlier aortic valve replacement should be consid-
ered even in asymptomatic patients before severe left ventricular hypertrophy or dys-
function develops. In younger patients, the largest possible prosthesis should be
implanted to minimize residual gradient; in elderly patients, complex operations
just to insert larger prostheses should be avoided.
A
ortic valve replacement (AVR) is recommended for symptomatic patients
with severe aortic stenosis to improve symptoms and increase survival.1
However, the onset of symptoms may be insidious, difficult to elicit,2 and
therefore unreliable in isolation for decision making. As a result, AVRmay be delayed
until the disease is in advanced stages, precluding optimal survival benefit. We pos-
tulate that survival after AVR is adversely influenced by preoperative severity of aor-
tic stenosis and its resultant secondary effects on left ventricular (LV) structure and
function.
Advances in prosthesis technology and improved operative and postoperative
management have decreased the risks of valve replacement; thus, operation should
be considered before the secondary effects on LV structure and function from severe
aortic stenosis decrease the benefit of valve replacement. To optimize survival after
AVR, we investigated these non-symptom factors, specifically, the detrimental effects
on survival of the complex interplay of severity of aortic stenosis, LV hypertrophy and
dysfunction, age, and small prosthesis size, all of which may play a role in decision
making, including the timing of operation.
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AV 5 aortic valve
AVR 5 aortic valve replacement
EF 5 ejection fraction
LV 5 left ventricular
Patients and Methods
Patients
Between October of 1991 and January of 2004, 3049 patients under-
went native AVR for aortic stenosis or mixed stenosis and regurgi-
tation, with or without coronary artery bypass grafting. Excluded
were patients with predominant aortic regurgitation rather than ste-
nosis, infective endocarditis, and rheumatic or other causes of aortic
valve (AV) disease, and those who underwent any other concomi-
tant valvar or aortic surgery. To avoid confounding of results with
prosthesis type and model, the study was limited to a single prosthe-
sis: the Carpentier-Edwards Perimount stented bovine pericardial
valve (Model 2700, Edwards Lifesciences Corp, Irvine, Calif),
one of the most commonly implanted prosthetic AVs. These patients
represent the most common spectrum of surgery for AV stenosis in
developed countries.
Preoperative patient characteristics, detailed echocardiographic
variables, and intraoperative data were retrieved from the Cardio-
vascular Information Registry, a database maintained concurrently
with patient care, and the Echocardiography Database (Table E1).
Both have been approved for use in research by the institutional re-
view board, with patient consent waived. Of the 3049 patients, 2859
(94%) had moderately severe or severe aortic stenosis and 1980
(65%) had pure aortic stenosis (Table E2).
Preoperative Echocardiography
Mean and peak instantaneous AV gradients were determined by
Doppler measurements, and native AV orifice area was calculated
by the continuity method.3 LV mass was calculated from end-
diastolic LV septal and posterior wall thicknesses, and internal
dimension was calculated by the formula validated by Devereux
and colleagues.4 LV function was graded qualitatively as follows:
ejection fraction (EF) 50% or greater, none; EF 40% to 49%,
mild; EF 35% to 39%, moderate; EF 26% to 34%, moderately se-
vere; and EF 25% or less, severe. We previously demonstrated the
prognostic sensitivity of this grading method.5
Operative Technique
AVR was performed on cardiopulmonary bypass at normothermia
or mild hypothermia. Antegrade and retrograde cold blood cardio-
plegia for myocardial protection was routine. Intraoperative transe-
sophageal echocardiography was used to confirm diagnoses and
assess prosthesis function.
Prosthesis Size
Prosthesis size was defined in terms of the geometric internal orifice
diameter (in millimeters) corresponding to the manufacturer’s label
size.6 Patient–prosthesis size was expressed as standardized orifice
size (prosthesis–patient Z value), the number of standard deviations
by which the internal orifice diameter deviated from the mean nor-The Journal of Thoramal aortic anulus diameter for the patient’s body surface area.6,7
Because a single-valve model was studied, these Z values are com-
parable to projected orifice area estimates.
End Point
The study end point was all-cause mortality from the date of oper-
ation. Patients were routinely followed 2, 5, 10, and 15 years after
AVR. These active follow-up data were supplemented by Social Se-
curity Death Index data with a common closing date of October 25,
2005.8,9 In all, 29 patients (0.95%) were untraced beyond hospital
discharge and 126 patients (4%) did not have a Social Security num-
ber for supplemental passive follow-up. Follow-up was 5.1 6 3.2
years (median 4.5 years), and 15,481 patient-years of data were
available for analysis; 25% of living patients were followed more
than 7.6 years, and 10% were followed more than 10 years. Survival
was estimated nonparametrically by the Kaplan-Meier method and
parametrically by a multiphase hazard model.10 Parametric model-
ing was used to resolve the number of phases of instantaneous risk
of death (hazard function) and to estimate shaping parameters. (For
additional details, see http://www.clevelandclinic.org/heartcenter/
hazard.)
Reference population survival estimates were generated from
equations for the US Life Tables for each patient according to
age, race, and sex. These were averaged overall and within sub-
groups of patients.
Data Analysis
To better understand the interplay of AV stenosis, LV structure and
function, age, and prosthesis size, we performed an ordered se-
quence of analyses, with extensive exploration of interactions, to
build a model of mortality (Tables E1 and E2 show the variables).
Although we assumed that sporadic missing values for variables
were missing at random and used mean value imputation, we incor-
porated missing-value indicator variables for these to adjust the
analysis for possible systematic biases; we found none.
Variable selection. Multivariable analyses were performed in
the multiphase hazard function domain. Variable selection, with
a P value criterion for retention of variables in the model of .05,
used bootstrap aggregation (bagging) from automated analysis of
500 bootstrap data sets.11,12 Variables appearing in 50% or more
of the models were retained as risk factors.
Additional analyses. Linear regression was used to identify cor-
relates of native AV orifice area, LV mass index, and prosthesis–
patient size, and logistic regression was used for LV function.
Presentation. Continuous variables are summarized as means6
standard deviations and as 15th, 50th (median), and 85th percentiles,
and categoric data are summarized as frequencies and percentages.
Analyses were performed using SAS version 9.1 (SAS, Inc, Cary,
NC). Uncertainty is expressed by 68% confidence limits equivalent
to 61 standard error.
Results
Overall Survival
Non–risk-adjusted survival estimates for the entire group at
30 days, 6 months, and 1, 5, and 10 years were 97%, 93%,
91%, 75%, and 47%, respectively (Figure E1, A). Risk
of death was highest immediately after operation
(Figure E1, B), decreased to its nadir approximately 1 yearcic and Cardiovascular Surgery c Volume 135, Number 6 1271
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Factor Coefficient 6 SD P Reliability (%)a
Early hazard phase
Older ageb 0.29 6 0.11 .01 45
Dilated left ventricle 0.46 6 0.19 .01 59
Smaller prosthesis size
Prosthesis–patient Z valuec 0.026 6 0.0073 .0005 90
Prosthesis–patient Z valued 0.054 6 0.021 .01 90
Calcified ascending aorta 0.36 6 0.14 .01 66
Left main stenosis ($70%) 0.63 6 0.21 .003 95
LCx stenosis (.0%) 0.30 6 0.15 .04 95
Hypertension 0.51 6 0.19 .008 82
Insulin-treated diabetes 0.53 6 0.21 .01 62
Renal disease 1.2 6 0.20 ,.0001 100
Lower creatinine clearancee 20.45 6 0.14 .002 100
Earlier date of operation 20.081 6 0.021 .0001 59
Late hazard phase
Older age 100
Ageb 0.86 6 0.15 ,.0001
AV (native) orifice areaf 2.9 6 1.2 .01 79
Interaction: age/AV orifice areag 20.56 6 0.25 .02
Larger LV mass indexh 0.22 6 0.104 .03 72
Interaction: LV mass index/AV (native) orifice areai 20.49 6 0.20 .01
Smaller prosthesis–patient size (Z value)j 0.22 6 0.104 .03 90
Interaction: prosthesis–patient Z-value/agek 20.060 6 0.024 .01
Interaction: prosthesis–patient Z-value/LV mass indexl 0.0505 6 0.0204 .01
LV dysfunctionm 0.33 6 0.095 .0006 92
Higher NYHA functional classn 0.23 6 0.081 .005 70
More previous cardiac operations 0.16 6 0.077 .04 46
Preoperative atrial fibrillation 0.37 6 0.13 .005 68
Ventricular arrhythmia 0.29 6 0.12 .01 74
LMT disease (.0%) 0.17 6 0.089 .05 97
Higher MV regurgitation gradeo 20.53 6 0.19 .006 86
Insulin-treated diabetes 0.54 6 0.14 .0002 98
Smoking 0.19 6 0.081 .02 74
History of peripheral arterial disease 0.29 6 0.086 .0006 77
Higher BUN 0.012 6 0.0035 .0005 100
Lower creatinine clearancee 20.28 6 0.12 .02 100
Lower hematocritp 20.52 6 0.19 .008 73
AV, Aortic valve; BUN, blood urea nitrogen; LCx, left circumflex; LMT, left main trunk; LV, left ventricular;MV, mitral valve; NYHA, New York Heart Association.
aPercent of times factor appeared in 500 bootstrap analyses. bExp(age/50), exponential transformation. cExp(prosthesis–patient Z value), exponential trans-
formation. d(1/exponential transformation of prosthesis–patient Z value), inverse transformation. eLn(creatinine clearance), logarithmic transformation. f(AV
orifice area)2, squared transformation. gInteraction: exp(age/50)/(AV orifice area)2. h(LV mass index/125)2, squared transformation. iInteraction: (AV orifice
area)2/(LV mass index/125)2. j(1/exponential transformation of prosthesis–patient Z value), inverse transformation. k(1/exponential transformation of prosthe-
sis–patient Z value)/exp(age/50). l(1/exponential transformation of prosthesis–patient Z value)/(LV mass index/125)2. mLV dysfunction grades . none, binary
variable. n(NYHA class I/II vs II/IV), binary variable. o(1/MV regurgitation11), inverse transformation. p(Hematocrit/40)2, squared transformation.postoperatively (early hazard phase), and then gradually in-
creased (late hazard phase). From approximately 2 years af-
ter valve replacement, survival was similar to that of matched
population estimates.
Risk Factors
Risk factors for death early after operation ( ,1 year) in-
cluded older age, LV dilatation, smaller prosthesis size,
calcified ascending aorta, and earlier date of operation1272 The Journal of Thoracic and Cardiovascular Surgery c Ju(Table 1). Risk factors for late death ( .1 year) included
similar factors, but specifically older age, greater degree of aor-
tic stenosis, greater LV mass index, smaller standardized
prothesis–patient size, interactions among these 4 factors,
and, in addition, LV dysfunction and advanced symptoms
(moderate to severe vs none or mild; Figure 1, A). Risk factors
associated with advanced symptoms included calcific aortic
stenosis and severe LV dysfunction (Table E3). More recent
patients were less likely to have advanced symptoms.ne 2008
Mihaljevic et al Surgery for Acquired Cardiovascular Disease
A
CDFigure 1. Survival after AVR according
to primary risk factors. Each symbol
represents a death, vertical bars are
68% confidence limits equivalent to
61 standard error, and numbers in pa-
rentheses are patients remaining at
risk. Solid lines are parametric esti-
mates. Dashed lines with correspond-
ing color represent corresponding
survival of an age, race, and sex-
matched population. A, Severity of
symptoms expressed as New York Heart
Association classes I and II versus III
and IV. Figure includes all patients in
study. B, Severity of aortic stenosis ex-
pressed as native AV orifice area. For
clarity, only patients with extreme
values are depicted, with the remaining
values between (15% had orifice area$
0.85 cm2 and 9.3% had orifice area< 0.5
cm2). C, Severity of LV hypertrophy, ex-
pressed as LV mass index. For clarity,
only patients with extreme values are
depicted, with the remaining values be-
tween (15% had mass < 100 g/m2 and
15% had mass $ 185 g/m2). D, LV dys-
function. All patients are depicted. E,
Age. All patients are depicted. F, Pros-
thesis size, expressed as prosthesis–
patient size (Z value). For clarity, only
patients with extreme values are de-
picted, with the remaining values be-
tween (15% had Z values > 0.5 and
13% had Z values # –1.5). NYHA, New
York Heart Association.The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 6 1273
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CDFigure 2. Nomograms of 10-year sur-
vival after AVR from the multivariable
analysis of death (Table 1). To produce
these risk-adjusted depictions, values
for the following variables were held
constant (unless depicted in the graph):
age, 73 years; no mitral regurgitation;
AV orifice area, 0.7 cm2; New York Heart
Association functional class I/II; date of
operation, January 2004; LV mass index,
135 g/m22; no ventricular arrhythmia; no
previous cardiac operation; left main
stenosis, $70%; left circumflex steno-
sis, >0%; smoker; peripheral arterial
disease; hypertensive; nondiabetic; no
renal disease; blood urea nitrogen, 19
mg/dL21; creatinine clearance, 65 mL/
min21; hematocrit, 38%. Solid lines are
parametric estimates, and dashed lines
are asymmetric 68% confidence limits.
Note the expanded vertical axes. A, LV
mass index and AV orifice area. B, Pros-
thesis–patient Z value and LV mass in-
dex. C, Prosthesis–patient Z value and
age.
The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 6 1275
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The non–risk-adjusted association of the 5 primary risk fac-
tors with mortality (severity of aortic stenosis, LV hypertro-
phy, LV function, age, and prosthesis–patient size) was
explored as follows:
Severity of aortic stenosis. Greater degree of severity of
aortic stenosis at operation was associated with increased
risk of late mortality (Figure 1, B). Patients with larger
valve area experienced better survival than their popula-
tion counterparts; those with smaller valve area had
poorer early survival that was less than that of their pop-
ulation counterparts. Patients with small valves were older
and more likely to have bicuspid morphology with LV
hypertrophy and had more severe LV dysfunction (Table
E4).
Left ventricular hypertrophy. Patients with severe LV
hypertrophy had higher late mortality that was distinctly
worse than that of their population counterparts (Figure 1,
C). They tended to be younger men with more severe aortic
stenosis and advanced symptoms (Table E5). A large propor-
tion of asymptomatic patients (145/303 [48%]) and mildly
symptomatic patients (616/1262 [49%]) had an LV mass in-
dex greater than the upper limit of normal for men ($135 g/
m22). Even when LV mass index was 185 g/m22 or greater,
17% of patients were asymptomatic and 14% of patients were
mildly symptomatic.
Left ventricular function. Patients with any LV dysfunc-
tion had considerably worse survival than those with normal
LV function and their population counterparts (Figure 1, D).
They had more severe aortic stenosis, but lower peak aortic
gradient, larger LV volumes, and greater degree of atrioven-
tricular valve regurgitation (Table E6). Further, some degree
of LV dysfunction had already occurred in 67 of 352 asymp-
tomatic patients (19%) and in 389 of 1507 mildly symptom-
atic patients (26%).
Age. Although older age was a risk factor for mortality,
survival of younger patients was less than that expected of
their population counterparts (Figure 1, E). In contrast, sur-
vival of elderly patients exceeded that of their counterparts
after the initial year of higher mortality. Patients younger
than age 65 years, however, constituted only 14% of cases.
Prosthesis–patient size. Patients with prostheses most
disproportionally small for body size had early survival sim-
ilar to those with the largest size, but slightly worse late sur-
vival (Figure 1, F). They were older and had more severe
aortic stenosis, tricuspid morphology, and less hypertrophy
(Table E7).
Interplay of Risk Factors
Native AV orifice area, LV mass index, age, and prosthesis–
patient size were not found to be additive (incremental) risk
factors but to interact with one another to modulate risk (Ta-
ble 1). As the degree of both aortic stenosis and LV hypertro-
phy increased, survival was greatly reduced (Figure 2, A).1276 The Journal of Thoracic and Cardiovascular Surgery c JuSurvival was also diminished when a small prosthetic valve
was used in patients with severe LV hypertrophy (Figure 2,
B). This effect was more pronounced in younger than in
older patients, particularly below prosthesis–patient Z values
of approximately –1.5 (Figure 2, C). Figure E2 illustrates
more fully the interplay of these 4 factors, with diminishing
order of effect on survival by age, followed by LV mass, na-
tive AV size, and prosthesis–patient size. In contrast with
these 4 factors, the presence of LV dysfunction was an incre-
mental risk factor only and did not interact with any other
factor.
Discussion
Principal Findings
Our results demonstrate that survival of patients with aortic
stenosis after AVR is primarily influenced by severity of
the stenosis and severity of LV hypertrophy and dysfunction
at operation. Although age was the strongest risk factor, sur-
vival of elderly patients was better than that of their age, race,
and sex-matched population counterparts, whereas survival
of younger patients was worse than expected, particularly
in those with severe LV hypertrophy in whom a small pros-
thesis was implanted.
Severity of Aortic Stenosis
More severe degrees of aortic stenosis were associated with
worse long-term survival, particularly when severe LV hy-
pertrophy was present. Chronic pressure overload in patients
with aortic stenosis results in concentric LV hypertrophy.
Although this represents a physiologic compensatory mech-
anism, severe LV hypertrophy may have deleterious effects
on the LV, including increased sensitivity to ischemia
(even in the absence of coronary artery disease) with conse-
quent systolic or diastolic dysfunction.13,14
Left Ventricular Hypertrophy
Although large LV mass has been associated with increased
in-hospital mortality of patients undergoing AVR for aortic
stenosis,15 our study provides evidence that links severe
LV hypertrophy to decreased long-term survival. This subop-
timal result of AVR is likely the result of irreversible myocar-
dial changes and fibrosis associated with severe LV
hypertrophy.16,17 LV reverse remodeling may be delayed
by a small prosthesis with high residual pressure gradient,
emphasizing the need for using the largest possible prosthesis
in patients with severe LV hypertrophy.
Left Ventricular Dysfunction
In advanced stages of disease, the hypertrophic process may
become inadequate to keep systolic wall stress within normal
limits, causing a decrease in EF.18 LV dysfunction was
a strong predictor of worse long-term survival in our study,
correlating with findings from previous studies.19ne 2008
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Worse survival of younger patients compared with their age,
race, sex-matched counterparts likely reflects the nature of
aortic stenosis in these adults. A large proportion had bicus-
pid aortic stenosis (Figure E3), a congenital anomaly of not
only the valve but also the proximal arterial tree that causes
a chronic, sustained systolic pressure load early in life, unlike
senile aortic stenosis.20 We speculate that the early onset of
myocardial hypertrophy early in life and chronicity of myo-
cardial changes are responsible for late myocardial dysfunc-
tion, even after successful AVR.
Many elderly patients with severe symptomatic aortic
stenosis are not referred for surgery because of their age,
although improvement in postoperative quality of life of oc-
togenarians after AVR is of similar magnitude to that of
younger patients.21,22 Survival of elderly patients in our
study was comparable to that of their age, race, and sex-
matched cohorts, which is in accord with previous find-
ings.6,23,24 These results suggest that AVR should be
strongly considered in all patients with severe aortic steno-
sis, irrespective of age.
Prosthesis Size
Numerous single-institution studies have identified prosthe-
sis–patient mismatch as a risk factor affecting survival after
AVR for aortic stenosis.25–32 However, these studies were
conducted on relatively few patients with various types of
aortic prostheses, resulting in heterogeneous study popula-
tions. In this study, we used a single type of prosthesis to
avoid confounding of prosthesis–patient size with prosthesis
type and model. The deleterious effect of small prosthesis–
patient size in younger patients was absent in elderly patients,
although the majority of small prostheses are implanted in the
elderly. This suggests that patient–prosthesis size has clinical
relevance (Figure E4); however, the effect was mild.
Limitations
This was a single-center observational clinical study on valve
replacement for the spectrum of severe aortic stenosis. How-
ever, the experience is large, as is the number of variables
available to analyze these insufficiently studied aspects of
treating aortic stenosis. Although asymptomatic patients
were a minority in this study, this is the largest cohort of
asymptomatic patients with aortic stenosis studied to date.
Implications for Guidelines
Current guidelines for treating severe aortic stenosis identify
the onset of symptoms as the critical point for AVR, although
symptoms are often subtle and not apparent to the physician
on routine examination.1,33 Our study underscores this point
in that approximately 50% of patients with mild or no symp-
toms by routine history had developed severe LV hypertro-
phy, and an important percentage of these had shown signs
of LV dysfunction before AVR. These findings suggestThe Journal of Thorthat relying on symptoms alone in therapeutic decision mak-
ing is inadequate. Thus, AVR should be performed before se-
vere LV hypertrophy and dysfunction develop. In younger
patients, the largest possible prosthesis should be implanted
to minimize the residual gradient. In elderly patients, com-
plex operations just to insert larger prostheses should be
avoided.
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Discussion
Dr Michael Mack (Dallas, Tex). You have performed a study that
is potentially a landmark one and likely to change the landscape of
the management of patients with critical aortic stenosis in the future.
I believe this study is that important. First, similar to the study by
Sarano in patients with asymptomatic mitral regurgitation, deter-
mining that an effective regurgitant orifice greater than 40 led to de-
creased survival, your study has defined some characteristics that
may lead to earlier operative management of patients with aortic ste-
nosis. Second, you have lent further clarity to the issue of patient–
prosthetic mismatch and perhaps saved some elderly patients from
undergoing the added risk of a root-enlarging procedure. You con-
clude that LV hypertrophy, LV dysfunction, extremely severe aortic
stenosis, older age, and a small prosthesis in younger patients de-
creased survival.1278 The Journal of Thoracic and Cardiovascular Surgery c JHowever, just as a movie critic needs to find something wrong
with a movie to maintain credibility as a critic, I can’t let you off
scot-free. The positive aspects your study include the fact that it is
a large study of more than 3000 patients who received a single
type of valve with a mean follow-up of 5 years. A sophisticated sta-
tistical analysis (and thank you for the explanation of the Z value) to
minimize confounding variables lends further clarity to the data.
However, this is not a population with isolated pure aortic stenosis,
with 56% of the patients having undergone concomitant coronary
bypass surgery and 35% of patients also having aortic regurgitation,
factors known to affect outcomes. In addition, only 13% of the pa-
tients were actually asymptomatic, yet significant management con-
clusions are drawn from this group.
My specific questions are as follows. First, you defined a small
prosthesis as a patient–prosthesis Z value of21.5, which corresponds
to 1.5 standard deviations below normal valve size for patient body
surface area. Why did you pick that Z value rather than perhaps 1 or 2?
Second, do you think that analysis of a population in whommore
than half of the patients underwent coronary artery bypass grafting
and one third of the patients had aortic regurgitation is valid for iso-
lated pure aortic stenosis?
Third, we now make clinical decisions in patients with asymp-
tomatic mitral regurgitation on the basis of an effective regurgitant
orifice greater than 40. Surgeons are familiar with echocardio-
graphic parameters of AV area, peak and mean gradients, jet veloc-
ity, and EF for making decisions. Should we now include an LV
mass index of greater than 135 in men or greater than 100 in women
as an indication for surgery in patients with critical aortic stenosis?
Four, as surgeons, we always want to know what to do different
when we go home. We use the red, yellow, green charts to choose
valve size now based on patient body surface area. Do your data
mean that we should now ignore those color charts for elderly patients?
Fifth, you state that guidelines should be changed to recommend
earlier AVR in asymptomatic patients, yet current guidelines, class
IIb, already recommend AVR in asymptomatic patients with either
an abnormal exercise test, likelihood of rapid progression based on
age, calcification and coronary artery disease, or extremely severe
aortic stenosis with a valve area of less than 0.6 cm2. How specifi-
cally would you recommend these current guidelines be changed?
Last, is it possible to come up with a patient management algo-
rithm factoring in all the variables you have identified, including
age, severity of aortic stenosis, LV dysfunction, LV mass index,
to guide the timing of surgical interventions?
Dr Mihaljevic. The first question was why did we define a Z
value of 21.5 as a cutoff? That was not truly a deliberate decision.
That was a result of an observation that by the Z value of 21.5 and
less, we noted the detrimental effects of the patient–prosthesis mis-
match that truly affected the outcomes of our patients, in particular
in those patients who had severe LV hypertrophy.
Your second question was whether we think that the analysis of
the population in whom more than 50% of patients underwent cor-
onary artery bypass grafting and one third of patients had severe aor-
tic regurgitation is truly representative of typical patients with aortic
stenosis. We think this is definitely the case. We purposely included
these patients, because when patients present to a surgeon or a cardi-
ologist with aortic stenosis, this is what typical patients look like.
These are the patients who almost always have some degree of aortic
regurgitation, but we were careful to exclude patients in whom the
aortic regurgitation was a predominant pathology. Furthermore, itune 2008
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CDis just a reality that most of these patients will have coronary artery
disease. The median age of patients in our study was 71 years, so
those patients are most likely going to have coronary artery disease,
and those are the patients we are going to see referred to us for aortic
stenosis. We don’t know if the coronary artery disease is present up
front until they undergo a coronary angiogram. We are currently
conducting a study in which we are particularly studying the effect
of coronary artery disease in patients and their outcomes when they
have severe aortic stenosis. Our preliminary findings show that the
presence of coronary artery disease triggers the symptoms in pa-
tients with aortic stenosis much earlier in the course, and those pa-
tients almost never develop severe LV hypertrophy, because they
become symptomatic much sooner in the course of their illness.
Your third question was regarding the echocardiographic param-
eters and whether we should use the LV mass index of greater than
135 as an indicator for surgery. I would absolutely concur with this
statement. We as surgeons have to be familiar with new echocardio-
graphic measurements, and just as you mentioned an example of mi-
tral valve surgery, I think we have to pay particular attention to the
ventricular effects of valvular heart disease. Ultimately all untreated
patients with aortic stenosis die not because their aortic stenosis gets
worse but because the effects of the aortic stenosis on the ventricle
caused it to fail. The presence of severe LV hypertrophy should not
any longer be viewed as a benign side effect of aortic stenosis, which
will be reversed after we replace the AV, but a significant contribu-
tor in the pathology or bad outcomes of these patients even after
a successful operation.
Your fourth question related to the sizes of the AV prostheses
that should be used for elderly patients with severe aortic stenosis.
As you saw from our presentation here, if we take a look at the entire
population of patients with aortic stenosis and compare those who
have severe patient–prosthesis mismatch with those who have pros-
theses that are larger than their anticipated AV area (standard AV
area), their overall survival is fairly similar. When we look at pa-
tient–prosthesis mismatch, we have to look at the different ages ofThe Journal of Thorathe patients undergoing operation, and in an elderly patient, the sur-
vival is truly not affected by a smaller prosthesis. So even implanta-
tion of a relatively small prosthesis was sufficient enough to relieve
the gradient to the extent that it was beneficial to survival. If we take
a look at our curves of survival of elderly patients, they benefited the
most from AVR. Their survival is better than the expected survival
of their matched cohorts, in contrast with our younger patients.
The fifth question is an important question about the current
guidelines and class IIb indications for AVR for asymptomatic pa-
tients. In our opinion, some of these class IIb indications should
be class I indications. For example, AV stenosis with an AV orifice
area of20.6 and a high gradient of 60 should truly be an indication
for surgery based on our data. As you can see from the curves shown
previously, patients with severe aortic stenosis and high gradients
did poorly, even after initial successful surgery. If we take a critical
look at the criteria that was used for the medical management, for
example, of patients with asymptomatic aortic stenosis, all articles
had a series with no more than 150 patients, with a follow-up that
was not more than 1.5 to 2 years. The longest observed survival
in patients with severe aortic stenosis who were asymptomatic and
underwent medical management was 67% 1-year event-free sur-
vival. The survival of patients who undergo surgery in the same con-
dition is approximately 10% to 15% better after the first year.
Obviously, they lack long-term follow-up because most of the pa-
tients develop symptoms anyhow and undergo surgery.
We hope that this article is going to be a significant contribution
to influence a change in the guidelines for treatment of patients with
asymptomatic aortic stenosis.
Your last question was, is it possible to come up with a patient
management algorithm to include all the risk factors and come up
with a new management scheme? Yes, absolutely. What we have
to take into consideration now is no longer only the AV orifice
area and gradients but also the degree of the LV hypertrophy, the
age of the patients, and the degree of the LV dysfunction at the
time of surgery, which most of us have been doing intuitively.cic and Cardiovascular Surgery c Volume 135, Number 6 1279
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CDFigure E1. Time -related survival after AVR. A,
Survival. Each symbol represents a death, vertical
bars 68% are confidence limits, and numbers in
parentheses are patients remaining at risk. Solid
line represents parametric estimates enclosed
within 68% confidence limits. Dash-dot-dash
line is survival for the age, race, and sex-matched
population. B, Instantaneous risk of death (hazard
function). Estimates are enclosed within 68% con-
fidence limits. Dash-dot-dash line represents haz-
ard function for the age, race, and sex-matched
population.1279.e1 The Journal of Thoracic and Cardiovascular Surgery c June 2008
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CDFigure E2. Ten -year survival after aortic value replacement according to interplay of primary risk factors. The 9
panels represent solutions to the multivariable equation by the indicated values of age, LV mass index, native AV
size, and prosthesis–patient size (Z value). Solid lines represent parametric estimates enclosed within 68% confi-
dence limits.The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 6 1279.e2
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CDFigure E3. Bicuspid AV morphology according to
age at AV replacement. Closed circles represent
percentage of patients with bicuspid valves in
decile age ranges; solid line is a trend line.1279.e3 The Journal of Thoracic and Cardiovascular Surgery c June 2008
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CDFigure E4. Nomogram for converting prosthesis–
patient Z value and body surface area to
Perimount pericardial prosthesis (Edwards Life-
sciences, Irvine, Calif) label size. When a patient
with a critical combination of risk factors (eg,
older age and large LV mass index) is identified,
use body surface area and minimum desired pros-
thesis–patient Z value (21.5, dashed horizontal
line) to convert to prosthesis label size for implan-
tation.The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 6 1279.e4
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CDTABLE E1. Variables used in analyses
Demography
Age (y), gender, weight (kg), height (cm), body surface area (m2), body mass index (kg/m22)
AV stenosis
Stenosis grade, regurgitation grade, orifice area (cm2), mean gradient (mm Hg), peak gradient (mm Hg)
AV morphology
Cusps: number of cusps, calcification, thickening, prolapse, tear, perforation, restricted cusp motion. Commissures: fused. Anulus: dilated.
Symptomatology
NYHA functional class (I–IV), emergency operation
LV geometry, function, and structure
Geometry
End-diastolic dimension (cm), end-diastolic volume (mL), end-diastolic volume index (mL/m22), end-systolic dimension (cm), end-systolic
volume (mL), end-systolic volume index (mL/m22), dilated left ventricle
Function
Fractional shortening, EF (%), degree of LV dysfunction (1 5 none, 2 5 mild, 3 5 moderate, 4 5 severe)
Structure
Posterior wall thickness (cm), intraventricular septal wall thickness (cm), mass (g), mass index (g/m22)
Other cardiovascular comorbidity
Ascending aorta: aneurysmal, calcified, dilated, arteriosclerosis; atrial fibrillation/flutter; ventricular arrhythmia; coronary artery disease
(stenosis$ 50% in left main trunk, left anterior descending coronary artery system, left circumflex coronary artery system, right coronary
artery system); previous myocardial infarction; other valve disease (tricuspid regurgitation, mitral regurgitation)
Noncardiac comorbidity
History of smoking, history of peripheral arterial disease, hypertension, insulin-treated diabetes, blood urea nitrogen (mg/dL21), creatinine
(mg/dL21), creatinine clearance (mL/min21), hematocrit (%)
AV prosthesis
Label size, index size (cm2/m22), standardized size (prosthesis–patient Z value)
Concomitant procedure
Coronary artery bypass grafting, internal thoracic artery graft used
Support
Aortic clamp time (minutes), cardiopulmonary bypass time (minutes)
Experience
Date of operation (years since January 1, 1991)
AV, Aortic valve; NYHA, New York Heart Association; LV, left ventricular; EF, ejection fraction.1279.e5 The Journal of Thoracic and Cardiovascular Surgery c June 2008
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CDTABLE E2. Patient, procedure, and prosthesis characteristics
Characteristic na No. (%) or Mean 6 SD
Demography
Age (y) 3049 73 6 8.3
Female 3049 1062 (35)
BSA (m2) 3044 1.95 6 0.24
AV stenosis
Lesion 3049
Pure stenosis 1980 (65)
Mixed stenosis 1069 (35)
Pure regurgitation 0 (0)
Orifice area (cm2) 2540 0.68 6 0.18
Mean gradient (mm Hg) 2614 46 6 17
Peak gradient (mm Hg) 2622 77 6 27
AV morphology 3049
Unicuspid 3 (0.098)
Bicuspid 710 (23)
Tricuspid 2335 (77)
Quadricuspid 1 (0.033)
Symptomatology
NYHA functional class 3049
I 408 (13)
II 1692 (56)
III 668 (22)
IV 281 (9.2)
Emergency operation 3049 17 (0.6)
LV geometry, function, and structure Geometry
End-diastolic dimension (cm) 2354 4.8 6 0.85
End-diastolic volume (mL) 2354 114 6 48
End-diastolic volume index (mL/m22) 2350 59 6 24
End-systolic dimension (cm) 2321 3.2 6 0.97
End-systolic volume (mL) 2321 46 6 36
End-systolic volume index (mL/m22) 2317 24 6 18
Function
Fractional shortening 2321 0.35 6 0.12
EF (%) 2175 50 6 13
Relative wall thickness (cm) 2247 0.57 6 0.16
LV dysfunction 2696
None 1898 (70)
Mild 232 (8.6)
Mild to moderate 76 (2.8)
Moderate 182 (6.8)
Moderately severe 149 (5.5)
Severe 159 (5.9)
Structure
Posterior wall thickness (cm) 2270 1.3 6 0.23
Intraventricular septal wall thickness (cm) 2315 1.4 6 0.29
Mass (g) 2240 277 6 92
Mass index (g/m22) 2236 142 6 44
Other cardiovascular comorbidity
Ascending aorta 3049
Calcified 854 (28)
Dilated 409 (13)
Arteriosclerosis 697 (23)
Atrial fibrillation/flutter 3049 201 (6.6)
Ventricular arrhythmia 3049 317 (10)
The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 6 1279.e6
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CDTABLE E2. Continued
Characteristic na No. (%) or Mean 6 SD
Complete heart block/pacer 3049 140 (4.6)
No. of previous non-valve cardiac operations 3049
0 2410 (79)
1 529 (17)
2 99 (3.2)
3 11 (0.4)
Presence of coronary artery diseaseb 3021 2022 (67)
LMT 3017 395 (13)
LAD system 3021 1618 (54)
LCx system 3018 1389 (46)
RCA system 3012 1462 (48)
Previous myocardial infarction 3049 933 (31)
Noncardiac comorbidity
Smoking 3011 1721 (57)
Peripheral arterial disease 3049 1637 (54)
Hypertension 2997 2140 (71)
Insulin-treated diabetes 2962 604 (20)
Renal disease 3049 178 (5.8)
BUN (mg/dL21) 2948 22 6 12
Creatinine (mg/dL21) 2953 1.2 6 0.92
Creatinine clearance (mL/min21) 2950 69 6 32
GFR (mL/min21) 2953 69 6 33
Hematocrit (%) 2529 38 6 5.2
Bilirubin (mg/dL21) 2385 0.72 6 0.64
AV prosthesis
Type
Carpentier-Edwards Perimount valve, model
2700 (Edwards Lifesciences, Irvine, Calif)
3049 3049 (100)
Label size
19 511 (17)
21 955 (31)
23 1076 (35)
25 421 (14)
27 78 (2.6)
29 8 (0.3)
Internal (geometric) orifice size
Area (cm2) 3049 1.6 6 0.26
Area index (cm2/m22) 3044 1.8 6 0.33
Standardized (Z value) 3044 20.48 6 0.94
Concomitant procedure
CABG 3049 1698 (56)
AV, Aortic valve; BSA, body surface area; BUN, blood urea nitrogen; CABG, coronary artery bypass grafting; EF, ejection fraction; GFR, glomerular filtration
rate; LAD, left anterior descending; LCx, left circumflex; LMT, left main trunk; LV, left ventricular;NYHA, New York Heart Association; RCA, right coronary artery;
SD, standard deviation. aData available. b$50% stenosis.1279.e7 The Journal of Thoracic and Cardiovascular Surgery c June 2008
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CDTABLE E3. Patient variables associated with higher likelihood of NYHA class III or IV
Variable Coefficient 6 SD P Reliability (%)a
Calcified AV 0.69 6 0.29 .02 72
Severe LV dysfunctionb 0.39 6 0.071 ,.0001 100
Higher grade of mitral regurgitationc 20.64 6 0.17 .0002 94
Female 0.35 6 0.094 .0002 85
Larger body mass index 0.0303 6 0.0072 ,.0001 98
More previous cardiac operations 0.23 6 0.082 .005 67
More coronary artery systems diseasedd 0.30 6 0.096 .002 97
Previous myocardial infarction 0.34 6 0.095 .0004 100
History of renal disease 0.33 6 0.16 .04 64
History of PAD 0.25 6 0.089 .005 49
Lower hematocrite 20.81 6 0.203 ,.0001 96
Earlier date of operation 20.069 6 0.013 ,.0001 99
AV, Aortic valve; LV, left ventricular; PAD, peripheral arterial disease; SD, standard deviation. aPercent of times factor appeared in 500 bootstrap analyses.
bLn(LV dysfunction), logarithmic transformation. c(1/mitral valve regurgitation11), inverse transformation. dNumber of coronary artery systems diseased:
0 or 1 versus 2 or 3. e(Hematocrit/40)2, squared transformation.The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 6 1279.e8
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CDTABLE E4. Patient variables associated with smaller native valve orifice area
Variable Coefficient 6 SD P Reliability (%)a
Older ageb 20.028 6 0.0054 ,.0001 97
Lower weightc 20.082 6 0.017 ,.0001 99
Female 20.035 6 0.0085 ,.0001 67
Lower grade of AV regurgitation 0.014 6 0.0032 ,.0001 97
Bicuspid morphology 20.018 6 0.008 .04 54
Larger LV mass indexd 0.090 6 0.0013 ,.0001 100
Higher grade of LV dysfunctione 20.033 6 0.0062 ,.0001 100
No previous myocardial infarction 20.026 6 0.0079 .001 100
No LCx system stenosis ($70%) 20.045 6 0.0078 ,.0001 100
No history of hypertension 20.021 6 0.0079 .008 88
No history of popliteal disease 20.022 6 0.0104 .03 60
Earlier date of operation 0.0046 6 0.0011 ,.0001 100
AV, Aortic valve; LCx, left circumflex; LV, left ventricular; SD, standard deviation. aPercent of times factor appeared in 500 bootstrap analyses. bExp(age/50),
exponential transformation. c80/weight, inverse transformation. d(125/LV mass index), inverse transformation. eLn(LV dysfunction grade), logarithmic trans-
formation.1279.e9 The Journal of Thoracic and Cardiovascular Surgery c June 2008
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CDTABLE E5. Patient variables associated with larger preoperative left ventricular mass index
Variable Coefficient 6 SD P Reliability (%)a
Male 20.079 6 0.083 .3 78
Interaction: Male/ageb 0.21 6 0.065 .002 97
Interaction: Female/agec 20.0602 6 0.104 .6 —
Higher AV mean gradientd 0.069 6 0.0067 ,.0001 100
Higher grade of aortic regurgitation 0.039 6 0.0054 ,.0001 100
NYHA functional class III/IV 0.032 6 0.013 .02 70
Ventricular arrhythmia 0.066 6 0.019 .0005 92
Complete heart block 0.14 6 0.028 ,.0001 100
History of hypertension 0.036 6 0.013 .007 76
Higher grade of mitral regurgitation 0.038 6 0.0065 ,.0001 100
History of renal disease 0.063 6 0.027 .02 100
Higher BUNe 0.046 6 0.016 .004 100
Lower hematocritf 20.075 6 0.028 .008 69
Earlier date of operation 20.021 6 0.0019 ,.0001 100
AV, Aortic valve; BUN, blood urea nitrogen; NYHA, New York Heart Association; SD, standard deviation. aPercent of times factor appeared in 500 bootstrap
analyses. bMale/(50/age), inverse transformation. cFemale/(50/age), inverse transformation. d(AV mean gradient/45)2, squared transformation. eLn(BUN), log-
arithmic transformation. f(Hematocrit/40)2, squared transformation.The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 6 1279.e10
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CDTABLE E6. Patient variables associated with left ventricular dysfunction
Variable Coefficient 6 SD P Reliability (%)a
Smaller native AV orifice areab 22.5 6 0.28 ,.0001 100
Lower AV peak gradient 20.031 6 0.0032 ,.0001 100
Larger LV end-systolic volume index 0.094 6 0.0057 ,.0001 100
Dilated LV 1.1 6 0.202 ,.0001 100
Higher grade of mitral regurgitation 0.32 6 0.063 ,.0001 99
Higher grade of tricuspid regurgitationc 20.76 6 0.22 .0007 99
Previous myocardial infarction 0.87 6 0.12 ,.0001 99
LCx system stenosis ($50%) 0.50 6 0.12 ,.0001 85
Complete heart block/pacer 0.86 6 0.25 .0006 67
Higher BUNd 0.503 6 0.14 .0005 84
AV, Aortic valve; BUN, blood urea nitrogen; LCx, left circumflex; LV, left ventricular; SD, standard deviation. aPercent of times factor appeared in 500 bootstrap
analyses. bLn(native AV area), logarithmic transformation. c(1/[TV regurgitation11]), inverse transformation. dLn(BUN), logarithmic transformation.1279.e11 The Journal of Thoracic and Cardiovascular Surgery c June 2008
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CDTABLE E7. Patient variables associated with smaller prosthesis–patient Z value
Variable Coefficient 6 SD P Reliability (%)a
Olderb 21.4 6 0.14 ,.0001 100
Female 20.75 6 0.032 ,.0001 100
Smaller AV orifice areac 0.204 6 0.056 .0003 85
Tricuspid morphology 20.46 6 0.035 ,.0001 100
Smaller LV mass index 0.0039 6 0.00038 ,.0001 100
Complete heart blocker/pacer 20.15 6 0.067 .03 64
History of hypertension 20.084 6 0.032 .01 52
RCA system stenosis (.0%) 20.11 6 0.031 .0003 94
Treated diabetes 20.11 6 0.036 .003 88
Lower GFRd 1.5 6 0.073 ,.0001 100
Higher creatinine clearancee 21.8 6 0.073 ,.0001 100
Earlier date of operation 0.020 6 0.0044 ,.0001 98
AV, Aortic valve; GFR, glomerular filtration rate; LV, left ventricular; RCA, right coronary artery; SD, standard deviation. aPercent of times factor appeared in 500
bootstrap analyses. bLn(age), logarithmic transformation. cAV orifice area2, squared transformation. dLn(GFR), logarithmic transformation. eLn(creatinine
clearance), logarithmic transformation.The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 6 1279.e12
